| scholarly article | Q13442814 |
| editorial | Q871232 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/TP.0B013E31817C4CB8 |
| P698 | PubMed publication ID | 18698239 |
| P50 | author | Paul Terasaki | Q7153959 |
| P2093 | author name string | Junchao Cai | |
| P2860 | cites work | Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause | Q43580802 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 377-383 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Human leukocyte antigen antibodies and chronic rejection: from association to causation | |
| P478 | volume | 86 |
| Q99711560 | Analysis of T and B Cell Epitopes to Predict the Risk of de novo Donor-Specific Antibody (DSA) Production After Kidney Transplantation: A Two-Center Retrospective Cohort Study |
| Q43284036 | Anti-HLA antibodies posttransplantation in children: do we know what it means? |
| Q35091339 | Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients |
| Q47810103 | Association Between HLA Antibodies and Different Sensitization Events in Renal Transplant Candidates. |
| Q37528715 | Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation. |
| Q42221525 | B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. |
| Q37602189 | B cells mediate chronic allograft rejection independently of antibody production |
| Q42038591 | B-cell tolerance in transplantation: is repertoire remodeling the answer? |
| Q34159016 | B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. |
| Q37742103 | Barriers to successful transplantation of the sensitized patient |
| Q56897769 | Belatacept: a novel immunosuppressive agent for kidney transplant recipients |
| Q47762688 | Binding of anti-HLA class I antibody to endothelial cells produce an inflammatory cytokine secretory pattern |
| Q26829578 | Biologics in organ transplantation |
| Q38062935 | Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: A review |
| Q33389918 | Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports |
| Q40417954 | C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study |
| Q34443169 | CD8+ T Cells Negatively Regulate IL-4–Dependent, IgG1-Dominant Posttransplant Alloantibody Production |
| Q36769749 | Calcineurin inhibitors: short-term friend, long-term foe? |
| Q37704862 | Capillary dilation and rarefaction are correlated with intracapillary inflammation in antibody-mediated rejection. |
| Q35929301 | Chronic progressive calcineurin nephrotoxicity: an overstated concept |
| Q39015291 | Clinical and immunological relevance of antibodies in solid organ transplantation |
| Q26780271 | Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation |
| Q52860032 | Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection. |
| Q37670811 | Computational Approaches to Facilitate Epitope-Based HLA Matching in Solid Organ Transplantation |
| Q35535173 | De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients |
| Q38168293 | Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation |
| Q82343270 | Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant |
| Q85084898 | Donor-specific HLA antibodies and graft function in children after renal transplantation |
| Q45164939 | Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation |
| Q46174297 | Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. |
| Q58850604 | Dynamics of anti-human leukocyte antigen antibodies after renal transplantation and their impact on graft outcome |
| Q41703961 | Dysregulated MicroRNA Expression and Chronic Lung Allograft Rejection in Recipients With Antibodies to Donor HLA. |
| Q38731333 | Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. |
| Q36575860 | Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques |
| Q37992135 | Everolimus: preventing organ rejection in adult kidney transplant recipients |
| Q34827355 | Expression of blood group genes by mesenchymal stem cells |
| Q92263424 | Frequency of Human Leukocyte Antigens and Donor Specific Antibodies in Long-Term Living Donor Kidney Transplantation |
| Q37815273 | Genetic modification of pigs for solid organ xenotransplantation. |
| Q34792059 | Genetics of transfusion recipient alloimmunization: can clues from susceptibility to autoimmunity pave the way? |
| Q37381100 | HLA Matching Trumps Donor Age: Donor-Recipient Pairing Characteristics That Impact Long-Term Success in Living Donor Kidney Transplantation in the Era of Paired Kidney Exchange |
| Q92418055 | Human Leukocyte Antigen Compatibility and De Novo Donor-Specific Antibodies in Long-term Renal Transplant Patients With Stable Graft Function |
| Q58122073 | IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade |
| Q34703678 | Identification of specificities of antibodies against human leukocyte antigens in blood donors |
| Q49297064 | Impact of complement component 3/4/5 single nucleotide polymorphisms on renal transplant recipients with antibody-mediated rejection |
| Q46897107 | Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations |
| Q33845320 | Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response |
| Q33842250 | Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study |
| Q37044541 | Ischemia-reperfusion injury accelerates human antibody-mediated transplant vasculopathy |
| Q34017594 | KIR and HLA-C interactions promote differential dendritic cell maturation and is a major determinant of graft failure following kidney transplantation |
| Q33974428 | Long-Term Effects of Antibodies against Human Leukocyte Antigens Detected by Flow Cytometry in the First Year after Renal Transplantation |
| Q38262909 | Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation |
| Q46318449 | Monitoring after renal transplantation: recommendations and caveats |
| Q33891669 | Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. |
| Q37935058 | On the future of HLA. |
| Q52647757 | PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. |
| Q90428722 | Parallels between antibody-mediated rejection and ischemic kidney injury with respect to B cell activation |
| Q41782407 | Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. |
| Q44458696 | Pediatric kidney recipients may benefit from monitoring for donor-specific antibodies |
| Q33608371 | Predicting alloreactivity in transplantation |
| Q54361889 | Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. |
| Q33755443 | Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys |
| Q90704817 | Preformed Angiotensin II Type-1 Receptor Antibodies Are Associated With Rejection After Kidney Transplantation: A Single-Center, Cohort Study |
| Q33755462 | Prevention trumps treatment of antibody-mediated transplant rejection |
| Q40330667 | Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study |
| Q39152736 | Renal Operational Tolerance Is Associated With a Defect of Blood Tfh Cells That Exhibit Impaired B Cell Help. |
| Q84403753 | Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT |
| Q52863308 | SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy. |
| Q36246918 | Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study |
| Q82046014 | Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation |
| Q92988221 | Sparse Convolutional Denoising Autoencoders for Genotype Imputation |
| Q37938922 | Strategies for B-lymphocyte repertoire remodeling in transplantation tolerance. |
| Q39017122 | Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg. |
| Q35669313 | Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection |
| Q57521747 | The Clinical Spectrum ofDe NovoDonor-Specific Antibodies in Pediatric Renal Transplant Recipients |
| Q42317060 | The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA. |
| Q36644337 | The Peripheral NK Cell Repertoire after Kidney Transplantation is Modulated by Different Immunosuppressive Drugs |
| Q56963763 | The clinical impact of donor-specific antibodies in heart transplantation |
| Q36719246 | The clinical impact of humoral immunity in pediatric renal transplantation. |
| Q38258153 | The increasing clinical importance of alloantibodies in kidney transplantation |
| Q37813404 | The pathology of chronic allograft dysfunction |
| Q33891696 | The role of B cells in solid organ transplantation. |
| Q37974520 | The role of HLA antibodies in allogeneic SCT: is the 'type-and-screen' strategy necessary not only for blood type but also for HLA? |
| Q24652613 | The role of causal criteria in causal inferences: Bradford Hill's "aspects of association" |
| Q36102133 | Tolerogenic therapies in transplantation. |
| Q50592282 | Transitional B Cells Predominantly Reconstituted After a Desensitization Therapy Using Rituximab Before Kidney Transplantation. |
| Q91554792 | Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation |
| Q38305297 | Transplantation tolerance; myth or reality? |
| Q34495912 | Transplanting the elderly: Balancing aging with histocompatibility. |
| Q28069336 | Unraveling the Role of Allo-Antibodies and Transplant Injury |
Search more.